Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea
NCT04612803Phase 3Withdrawn
- Sponsor
- University of Cincinnati
- Start
- Feb 2020
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
A Phase 3 trial of cetirizine, famotidine in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by University of Cincinnati. Planned start Feb 2020; status: withdrawn.
02
Drugs
cetirizinefamotidine
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT04612803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612803.